A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
Plasmodium falciparum
Pfs48/45
Transmission-blocking
Vaccine
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
23 Apr 2024
23 Apr 2024
Historique:
received:
09
11
2023
accepted:
02
04
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
22
4
2024
Statut:
epublish
Résumé
The stalling global progress in malaria control highlights the need for novel tools for malaria elimination, including transmission-blocking vaccines. Transmission-blocking vaccines aim to induce human antibodies that block parasite development in the mosquito and mosquitoes becoming infectious. The Pfs48/45 protein is a leading Plasmodium falciparum transmission-blocking vaccine candidate. The R0.6C fusion protein, consisting of Pfs48/45 domain 3 (6C) and the N-terminal region of P. falciparum glutamate-rich protein (R0), has previously been produced in Lactococcus lactis and elicited functional antibodies in rodents. Here, we assess the safety and transmission-reducing efficacy of R0.6C adsorbed to aluminium hydroxide with and without Matrix-M™ adjuvant in humans. In this first-in-human, open-label clinical trial, malaria-naïve adults, aged 18-55 years, were recruited at the Radboudumc in Nijmegen, the Netherlands. Participants received four intramuscular vaccinations on days 0, 28, 56 and 168 with either 30 µg or 100 µg of R0.6C and were randomised for the allocation of one of the two different adjuvant combinations: aluminium hydroxide alone, or aluminium hydroxide combined with Matrix-M1™ adjuvant. Adverse events were recorded from inclusion until 84 days after the fourth vaccination. Anti-R0.6C and anti-6C IgG titres were measured by enzyme-linked immunosorbent assay. Transmission-reducing activity of participants' serum and purified vaccine-specific immunoglobulin G was assessed by standard membrane feeding assays using laboratory-reared Anopheles stephensi mosquitoes and cultured P. falciparum gametocytes. Thirty-one participants completed four vaccinations and were included in the analysis. Administration of all doses was safe and well-tolerated, with one related grade 3 adverse event (transient fever) and no serious adverse events occurring. Anti-R0.6C and anti-6C IgG titres were similar between the 30 and 100 µg R0.6C arms, but higher in Matrix-M1™ arms. Neat participant sera did not induce significant transmission-reducing activity in mosquito feeding experiments, but concentrated vaccine-specific IgGs purified from sera collected two weeks after the fourth vaccination achieved up to 99% transmission-reducing activity. R0.6C/aluminium hydroxide with or without Matrix-M1™ is safe, immunogenic and induces functional Pfs48/45-specific transmission-blocking antibodies, albeit at insufficient serum concentrations to result in transmission reduction by neat serum. Future work should focus on identifying alternative vaccine formulations or regimens that enhance functional antibody responses. The trial is registered with ClinicalTrials.gov under identifier NCT04862416.
Sections du résumé
BACKGROUND
BACKGROUND
The stalling global progress in malaria control highlights the need for novel tools for malaria elimination, including transmission-blocking vaccines. Transmission-blocking vaccines aim to induce human antibodies that block parasite development in the mosquito and mosquitoes becoming infectious. The Pfs48/45 protein is a leading Plasmodium falciparum transmission-blocking vaccine candidate. The R0.6C fusion protein, consisting of Pfs48/45 domain 3 (6C) and the N-terminal region of P. falciparum glutamate-rich protein (R0), has previously been produced in Lactococcus lactis and elicited functional antibodies in rodents. Here, we assess the safety and transmission-reducing efficacy of R0.6C adsorbed to aluminium hydroxide with and without Matrix-M™ adjuvant in humans.
METHODS
METHODS
In this first-in-human, open-label clinical trial, malaria-naïve adults, aged 18-55 years, were recruited at the Radboudumc in Nijmegen, the Netherlands. Participants received four intramuscular vaccinations on days 0, 28, 56 and 168 with either 30 µg or 100 µg of R0.6C and were randomised for the allocation of one of the two different adjuvant combinations: aluminium hydroxide alone, or aluminium hydroxide combined with Matrix-M1™ adjuvant. Adverse events were recorded from inclusion until 84 days after the fourth vaccination. Anti-R0.6C and anti-6C IgG titres were measured by enzyme-linked immunosorbent assay. Transmission-reducing activity of participants' serum and purified vaccine-specific immunoglobulin G was assessed by standard membrane feeding assays using laboratory-reared Anopheles stephensi mosquitoes and cultured P. falciparum gametocytes.
RESULTS
RESULTS
Thirty-one participants completed four vaccinations and were included in the analysis. Administration of all doses was safe and well-tolerated, with one related grade 3 adverse event (transient fever) and no serious adverse events occurring. Anti-R0.6C and anti-6C IgG titres were similar between the 30 and 100 µg R0.6C arms, but higher in Matrix-M1™ arms. Neat participant sera did not induce significant transmission-reducing activity in mosquito feeding experiments, but concentrated vaccine-specific IgGs purified from sera collected two weeks after the fourth vaccination achieved up to 99% transmission-reducing activity.
CONCLUSIONS
CONCLUSIONS
R0.6C/aluminium hydroxide with or without Matrix-M1™ is safe, immunogenic and induces functional Pfs48/45-specific transmission-blocking antibodies, albeit at insufficient serum concentrations to result in transmission reduction by neat serum. Future work should focus on identifying alternative vaccine formulations or regimens that enhance functional antibody responses.
TRIAL REGISTRATION
BACKGROUND
The trial is registered with ClinicalTrials.gov under identifier NCT04862416.
Identifiants
pubmed: 38649867
doi: 10.1186/s12916-024-03379-y
pii: 10.1186/s12916-024-03379-y
doi:
Banques de données
ClinicalTrials.gov
['NCT04862416']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170Subventions
Organisme : H2020 Societal Challenges
ID : 733273
Informations de copyright
© 2024. The Author(s).
Références
Blagborough AM, Churcher TS, Upton LM, Ghani AC, Gething PW, Sinden RE. Transmission-blocking interventions eliminate malaria from laboratory populations. Nat Commun. 2013;4(1):1812.
doi: 10.1038/ncomms2840
pubmed: 23652000
Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, et al. malERA: an updated research agenda for malaria elimination and eradication. PLoS Med. 2017;14(11):e1002456.
doi: 10.1371/journal.pmed.1002456
pubmed: 29190300
pmcid: 5708604
Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al. Reducing Plasmodium falciparum malaria transmission in africa: a model-based evaluation of intervention strategies. PLoS Med. 2010;7(8):e1000324.
doi: 10.1371/journal.pmed.1000324
pubmed: 20711482
pmcid: 2919425
Sauerwein RW, Bousema T. Transmission blocking malaria vaccines: assays and candidates in clinical development. Vaccine. 2015;33(52):7476–82.
doi: 10.1016/j.vaccine.2015.08.073
pubmed: 26409813
Targett GA, Greenwood BM. Malaria vaccines and their potential role in the elimination of malaria. Malar J. 2008;7(1):S10.
doi: 10.1186/1475-2875-7-S1-S10
pubmed: 19091034
pmcid: 2604874
Duffy PE. Transmission-blocking vaccines: harnessing herd immunity for malaria elimination. Expert Rev Vaccines. 2021;20(2):185–98.
doi: 10.1080/14760584.2021.1878028
pubmed: 33478283
Healy SA, Anderson C, Swihart BJ, Mwakingwe A, Gabriel EE, Decederfelt H, et al. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. J Clin Investig. 2021;131(7):e146221.
doi: 10.1172/JCI146221
pubmed: 33561016
pmcid: 8011888
Sagara I, Healy SA, Assadou MH, Kone M, Swihart BJ, Kwan JL, et al. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial. Lancet Infect Dis. 2023;23(11):1266–79.
doi: 10.1016/S1473-3099(23)00276-1
pubmed: 37499679
van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA, Dodemont HJ, et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell. 2001;104(1):153–64.
doi: 10.1016/S0092-8674(01)00199-4
pubmed: 11163248
Fabra-Garcia A, Hailemariam S, de Jong RM, Janssen K, Teelen K, van de Vegte-Bolmer M, et al. Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes. Immunity. 2023;56(2):406-19 e7.
doi: 10.1016/j.immuni.2023.01.009
pubmed: 36792574
pmcid: 9942873
Stone WJR, Campo JJ, Ouédraogo AL, Meerstein-Kessel L, Morlais I, Da D, et al. Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity. Nat Commun. 2018;9(1):558.
doi: 10.1038/s41467-017-02646-2
pubmed: 29422648
pmcid: 5805765
Kundu P, Semesi A, Jore MM, Morin MJ, Price VL, Liang A, et al. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45. Nat Commun. 2018;9(1):4458.
doi: 10.1038/s41467-018-06742-9
pubmed: 30367064
pmcid: 6203815
Outchkourov N, Vermunt A, Jansen J, Kaan A, Roeffen W, Teelen K, et al. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. J Biol Chem. 2007;282(23):17148–56.
doi: 10.1074/jbc.M700948200
pubmed: 17426022
van der Boor SC, Smit MJ, van Beek SW, Ramjith J, Teelen K, van de Vegte-Bolmer M, et al. Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. Lancet Infect Dis. 2022;22(11):1596–605.
Singh SK, Roeffen W, Mistarz UH, Chourasia BK, Yang F, Rand KD, et al. Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine. Microb Cell Fact. 2017;16(1):97.
doi: 10.1186/s12934-017-0710-0
pubmed: 28569168
pmcid: 5452637
Singh SK, Plieskatt J, Chourasia BK, Fabra-García A, Garcia-Senosiain A, Singh V, et al. A reproducible and scalable process for manufacturing a Pfs48/45 based Plasmodium falciparum transmission-blocking vaccine. Front Immunol. 2021;11:606266.
Singh SK, Roeffen W, Andersen G, Bousema T, Christiansen M, Sauerwein R, Theisen M. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies. Vaccine. 2015;33(16):1981–6.
doi: 10.1016/j.vaccine.2015.02.040
pubmed: 25728318
Singh SK, Thrane S, Chourasia BK, Teelen K, Graumans W, Stoter R, et al. Pfs230 and Pfs48/45 fusion proteins elicit strong transmission-blocking antibody responses against Plasmodium falciparum. Front Immunol. 2019;10:1256.
doi: 10.3389/fimmu.2019.01256
pubmed: 31231386
pmcid: 6560166
Reimer JM, Karlsson KH, Lövgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One. 2012;7(7):e41451.
doi: 10.1371/journal.pone.0041451
pubmed: 22844480
pmcid: 3402407
Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, Stertman L. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66(2):224–33.
doi: 10.1007/s12026-018-8991-x
pubmed: 29594879
pmcid: 5899102
Food and Drug Administration CfBEaR. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007.
Singh SK, Thrane S, Janitzek CM, Nielsen MA, Theander TG, Theisen M, et al. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. Vaccine. 2017;35(30):3726–32.
doi: 10.1016/j.vaccine.2017.05.054
pubmed: 28578824
Clatworthy AJ, Jones LV, Whitehouse MJ. The gas chromatography mass spectrometry of the major metabolites of flurazepam. Biomed Mass Spectrom. 1977;4(4):248–54.
doi: 10.1002/bms.1200040411
pubmed: 21004
van der Kolk M, De Vlas SJ, Saul A, van de Vegte-Bolmer M, Eling WM, Sauerwein RW. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology. 2005;130(Pt 1):13–22.
doi: 10.1017/S0031182004006067
pubmed: 15700753
Ramjith J, Alkema M, Bradley J, Dicko A, Drakeley C, Stone W, Bousema T. Quantifying reductions in plasmodium falciparum infectivity to mosquitos: a sample size calculator to inform clinical trials on transmission-reducing interventions. Front Immunol. 2022;13:899615.
doi: 10.3389/fimmu.2022.899615
pubmed: 35720362
pmcid: 9205189
Churcher TS, Blagborough AM, Delves M, Ramakrishnan C, Kapulu MC, Williams AR, et al. Measuring the blockade of malaria transmission–an analysis of the standard membrane feeding assay. Int J Parasitol. 2012;42(11):1037–44.
doi: 10.1016/j.ijpara.2012.09.002
pubmed: 23023048
Esen M, Kremsner PG, Schleucher R, Gassler M, Imoukhuede EB, Imbault N, et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine. 2009;27(49):6862–8.
doi: 10.1016/j.vaccine.2009.09.011
pubmed: 19755144
Moon JE, Greenleaf ME, Regules JA, Debois M, Duncan EH, Sedegah M, et al. A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS, S/AS01(E) in a controlled human malaria infection challenge. Vaccine. 2021;39(43):6398–406.
doi: 10.1016/j.vaccine.2021.09.024
pubmed: 34593270
Moon JE, Ockenhouse C, Regules JA, Vekemans J, Lee C, Chuang I, et al. A phase IIa controlled human malaria infection and immunogenicity study of RTS, S/AS01E and RTS, S/AS01B delayed fractional dose regimens in malaria-naive adults. J Infect Dis. 2020;222(10):1681–91.
doi: 10.1093/infdis/jiaa421
pubmed: 32687161
pmcid: 7552430
Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, et al. Fractional third and fourth dose of RTS, S/as01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016;214(5):762–71.
doi: 10.1093/infdis/jiw237
pubmed: 27296848
Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, et al. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med. 2021;2(6):701-19.e19.
doi: 10.1016/j.medj.2021.03.014
pubmed: 34223402
Demonbreun AR, Sancilio A, Velez MP, Ryan DT, Saber R, Vaught LA, et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine. 2021;38:101018.
doi: 10.1016/j.eclinm.2021.101018
pubmed: 34278286
pmcid: 8276631
Keshavarz B, Richards NE, Workman LJ, Patel J, Muehling LM, Canderan G, et al. Trajectory of IgG to SARS-CoV-2 after vaccination with BNT162b2 or mRNA-1273 in an employee cohort and comparison with natural infection. Front Immunol. 2022;13:850987.
doi: 10.3389/fimmu.2022.850987
pubmed: 35386716
pmcid: 8978955
Singh SK, Plieskatt J, Chourasia BK, Singh V, Bengtsson KL, Reimer JM, et al. Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine. npj Vaccines. 2021;6(1):120.
doi: 10.1038/s41541-021-00383-8
pubmed: 34642303
pmcid: 8511065
Simwela NV, Waters AP. Current status of experimental models for the study of malaria. Parasitology. 2022;149(6):1–22.
doi: 10.1017/S0031182021002134
pubmed: 35357277
Langhorne J, Buffet P, Galinski M, Good M, Harty J, Leroy D, et al. The relevance of non-human primate and rodent malaria models for humans. Malar J. 2011;10:23.
doi: 10.1186/1475-2875-10-23
pubmed: 21288352
pmcid: 3041720
Laurens MB. Novel malaria vaccines. Hum Vaccin Immunother. 2021;17(11):4549–52.
doi: 10.1080/21645515.2021.1947762
pubmed: 34347570
pmcid: 8827625
Dolgin E. How COVID unlocked the power of RNA vaccines. Nature. 2021;589(7841):189–91.
doi: 10.1038/d41586-021-00019-w
pubmed: 33437061
Thrane S, Janitzek CM, Matondo S, Resende M, Gustavsson T, de Jongh WA, et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnology. 2016;14:30.
doi: 10.1186/s12951-016-0181-1
pubmed: 27117585
pmcid: 4847360
Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, et al. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci Rep. 2016;6:19234.
doi: 10.1038/srep19234
pubmed: 26781591
pmcid: 4725971
de Jong RM, Tebeje SK, Meerstein-Kessel L, Tadesse FG, Jore MM, Stone W, Bousema T. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites. Immunol Rev. 2020;293(1):190–215.
doi: 10.1111/imr.12828
pubmed: 31840844
Sauerwein RW, Plieskatt J, Theisen M. 40 Years of Pfs48/45 research as a transmission-blocking vaccine target of Plasmodium falciparum malaria. Am J Trop Med Hyg. 2022;107(Suppl 3):22–6.
McLeod B, Mabrouk MT, Miura K, Ravichandran R, Kephart S, Hailemariam S, et al. Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses. Immunity. 2022;55(9):1680-92 e8.
doi: 10.1016/j.immuni.2022.07.015
pubmed: 35977542
pmcid: 9487866